Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


"Authorized" Generics Violate Predatory Pricing Laws, Mylan Lawsuit Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Mylan alleges P&G and Watson violated Robinson-Patman and Sherman antitrust laws by selling an "authorized" generic of Macrobid below cost with the intent to monopolize the market. The lawsuit is aimed at preventing authorized generics during Mylan's 180-day exclusivity period for Norvasc, Levaquin and Ditropan XL.

Related Content





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts